Insider buying last 90 days
No open-market insider purchases were filed for CELC in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every CELC insider filing, plotted on the chart in Gekko.Open CELC in Gekko
NASDAQ: CELC
Celcuity (CELC) Stock Analysis & Forecast
Oct 12 close
$65.85−2.09 (−3.1%)
Gekko Brief
AI summaryOct 12 closeCelcuity's week centers on the US commercial launch of REVTORPYK for advanced breast cancer, alongside submission of an sNDA to broaden its use, and the appointment of a new finance executive to the board as the company shifts from clinical development toward commercial execution. The launch news drove a sharp decline, with one report noting the stock down 17.3% following the event. Separately, Celcuity announced multiple presentations at the ESMO Congress 2026, including a late-breaking rapid oral presentation and poster sessions covering gedatolisib data in advanced breast cancer and metastatic castration-resistant prostate cancer. Several Form 4 and Form 3 filings from insiders were also logged during the period.
The stock closed at $65.85, down 3.1%, sitting below both its 50-day average of $85.42 and 200-day average of $103.47, with the shorter average below the longer one, reflecting a sustained downtrend; one-month return stands at -21.1% and six-month at -45.3%, against a 52-week range of $45.03 to $151.02. The GekkoIndex reads 73, placing the stock in the Buying zone. Price sits 40.5% below Gekko Fair Value of $110.67.
Over the next 20 trading days, no earnings report is expected, with the next date set for 11 November 2026, 29 days out. No insider, Congress, or unusual options activity appears in their respective windows, though one trailblazer holder is on record. Seasonality data shows the next 20 trading days have averaged +18.8% over 5 years, rising in 4 of them. Typical 20-day price movement runs around 10.3%, worth noting given recent volatility.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Celcuity price vs fair value
Close $65.85200-day averageGekko Fair Value $110.67
Celcuity quick facts
- Market cap
- $3.21B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$4.17
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 0.11
- Volume
- 1.02M avg 1.17M
- 1-year return
- +33.1%
- Typical daily move
- ±7.5%
- Typical 20-day move
- ±10.3%
- 50-day average
- $85.42
- 200-day average
- $103.47
- Next earnings
- Nov 11 after close
- Shares outstanding
- 48.93M
Celcuity swing-trade checklist
Celcuity scores 4 supportive, 0 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive0 mixed1 headwind
- Trendheadwind
Below 50 and 200-day
Close $65.85 is below the 50-day ($85.42) and 200-day ($103.47) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
73, Buying
Reading 73 is in the Buying zone.
See the GekkoIndex - Fair valuesupportive
40.5% below
Price is 40.5% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 30 days
Next report Nov 11, 2026, 30 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+18.8% on average
From this point in the calendar, the next 20 trading days averaged +18.8% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Celcuity stock chart and price history
Celcuity closed at $65.85 on Oct 12, 2026, +33.1% over the past year, inside a 52-week range of $45.03 to $151.02.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −21.1%
- 3 months
- −40.7%
- 6 months
- −45.3%
- 1 year
- +33.1%
The full CELC chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open CELC in Gekko
Follow Celcuity through every session
Put CELC on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track CELC in GekkoFree for 7 days. No credit card required.
About Celcuity
Celcuity works in cellular analysis, with a focus on identifying previously unrecognized forms of cancer and turning that research into diagnostic tests. The goal of these tests is to help guide cancer patients toward targeted therapies that produce better clinical results. The company is best known for its CELx platform, a technology built to serve this purpose.
The CELx platform examines a patient's own living tumor cells to pinpoint the abnormal cellular activity behind their cancer, then matches that activity to a targeted treatment capable of addressing it. This diagnostic approach is already at a stage where it can be offered commercially, positioning the company's work around clinical use for cancer patients rather than early-stage research alone.
Celcuity was established in January 2012 by Brian F. Sullivan and Lance G. Laing, and its headquarters are in Minneapolis, Minnesota. The company's shares are listed on the NASDAQ under the ticker CELC.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- celcuity.com
Celcuity GekkoIndex: the smart money zone
Celcuity’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 73, in the Buying zone, up 3.6 points over five sessions.
73Buying
Up 3.6 points over five sessions, from the Accumulation zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying (current zone) | 26 | +3.7% | +12.8% |
| Accumulation | 199 | +1.7% | +4.3% |
| Neutral | 403 | +2.2% | +11.7% |
| Distribution | 44 | +1.6% | +13.0% |
| Selling | 10 | +5.3% | +13.2% |
Average CELC share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +3.1% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
See every daily GekkoIndex reading plotted over the CELC price, zone by zone.Track CELC in Gekko
Is Celcuity stock overvalued? Gekko Fair Value
Celcuity trades 40.5% below Gekko Fair Value of $110.67, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Celcuity shares are worth, recalculated every trading day.
$110.67
Gekko Fair Value, Oct 9, 2026
40.5% Undervalued
At the end of Aug 2026 the price was 35.3% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open CELC in Gekko
Celcuity insider and Congress trading
No open-market insider purchases were filed for Celcuity, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in CELC were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for CELC, plotted on the chart in Gekko.Open CELC in Gekko
Buybacks
Celcuity has been buying back its own shares.
- Bought back, year ended Dec 31, 2018
- $55K
- As a share of market cap
- 0.00%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds CELC.
1added0opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Celcuity earnings: next date and track record
Celcuity reports on Nov 11, 2026, after the close (30 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 11, 2026
Expected after the close, 30 days away
- EPS estimate
- −$1.45
- Revenue estimate
- $2.40M
5 of 8reports beat the EPS estimate
±7.3%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 13, 2026 AI summary
- What they said
- Celcuity received FDA approval for Revtopik (gedatolisib) in HR+/HER2- advanced breast cancer without PIK3CA mutation, with NCCN Category 1 preferred designation. Phase 3 VIKTORIA-1 PIK3CA mutant cohort showed gedatolisib triplet achieved 11.1 months median PFS vs 5.6 months for alpelisib (HR 0.50). Company plans sNDA submission in Q3 2026 and expanded VIKTORIA-2 study to include treatment-naive endocrine-sensitive patients. Commercial launch of Revtopik expected late Q3 2026.
- Guidance
- Revtopik commercial shipping targeted for late Q3 2026. sNDA submission for PIK3CA mutant indication planned Q3 2026. VIKTORIA-2 expansion positions gedatolisib for potential first-line use across nearly all HR+/HER2- patients regardless of PIK3CA status or endocrine sensitivity.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 13, 2026 | −$1.44 est −$1.16 | — est $4.42M | −0.1% |
| May 14, 2026 | −$0.97 est −$1.06 | — est $2.94M | +10.6% |
| Mar 25, 2026 | −$0.73 est −$1.05 | — est $1.28M | +12.5% |
| Nov 12, 2025 | −$0.92 est −$1.02 | — | +8.6% |
| Aug 14, 2025 | −$1.04 est −$0.90 | — | −1.1% |
| May 14, 2025 | −$0.81 est −$0.86 | — | −2.8% |
| Mar 31, 2025 | −$0.75 est −$0.67 | $121K | −9.3% |
| Nov 14, 2024 | −$0.65 est −$0.70 | — | −13.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Celcuity stock forecast and analyst price targets
Analysts’ average 12-month price target for Celcuity is $156.91, +138.3% from the last close, from 10 firms rating the stock in the last 90 days.
$156.91consensus 12-month target, +138.3% from the last close
Now $65.85Avg $156.91
Low $134High $177
Each firm’s latest rating in the last 90 days: 10 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 1 | H.C. Wainwright | $155 | +135.4% |
| Oct 1 | Leerink Partners | $147 | +123.2% |
| Sep 30 | Needham | $134 | +103.5% |
| Aug 18 | Craig-Hallum | $173 | +162.7% |
| Aug 16 | Guggenheim | $175 | +165.8% |
+12.8%average 20-day move after past Buying readings
+18.8%average move over the next 20 trading days in the last 5 years
±7.5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Celcuity seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Celcuity averaged +18.8% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +3.6% | 4 of 5 |
| Next 10 trading days | +14.4% | 3 of 5 |
| Next 15 trading days | +20.1% | 4 of 5 |
| Next 20 trading days | +18.8% | 4 of 5 |
| Next 30 trading days | +24.7% | 2 of 5 |
For scale, CELC’s typical 20-trading-day move in either direction is about 10.3%.
Celcuity market cap and key statistics
Celcuity’s market cap is $3.21B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $3.21B
- EPS, TTM
- −$4.17
- Gekko Fair Value
- $110.67
Trading
- Volume
- 1.02M
- Avg volume, 20 days
- 1.17M
- 52-week high
- $151.02
- 52-week low
- $45.03
- Shares outstanding
- 48.93M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -1434%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.11
- Typical daily move
- ±7.5%
- Typical 20-day move
- ±10.3%
Celcuity stock news this week
Coverage of Celcuity this week reads positive: 4 positive, 3 neutral and 2 negative headlines.
- Form 4 Celcuity LLC For: 11 October By Investing.comInvesting.com South Africa, Oct 12
- Precision Trading with Celcuity Inc. (CELC) Risk ZonesStock Traders Daily, Oct 11
- Does REVTORPYK Launch Change The Bull Case For Celcuity Stock?Simply Wall Street, Oct 10
- Form 4 Celcuity LLC For: 10 October By Investing.comInvesting.com Canada, Oct 10
- Celcuity (CELC) Is Down 17.3% After REVTORPYK US Launch And sNDA Filing News EventYahoo Finance, Oct 8
- Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026GlobeNewswire, Oct 6
Celcuity peers
Celcuity’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 18.2% above |
| ABTAbbott Laboratories | Neutral | 14.7% below |
| DHRDanaher | Neutral | 4.5% above |
| ISRGIntuitive Surgical | Neutral | 18.8% above |
| MDTMedtronic | Neutral | 22.9% below |
| SYKStryker | Accumulation | 12.6% below |
A peer links to its own page where one exists.
Celcuity stock FAQ
What is Celcuity’s market cap?
Celcuity’s market cap is $3.21B at the Oct 12, 2026 close of $65.85, with 48.93M shares outstanding.
What is the Celcuity stock forecast?
The consensus analyst 12-month price target for Celcuity is $156.91, +138.3% from the last close. Of the 10 firms that rated the stock in the last 90 days, 10 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Celcuity stock overvalued or undervalued?
On Gekko’s estimate Celcuity is undervalued: the Oct 12, 2026 close of $65.85 is 40.5% below Gekko Fair Value of $110.67. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Celcuity report earnings next?
Celcuity is expected to report on Nov 11, 2026, after the market closes (30 days away). Analysts expect earnings of −$1.45 per share on revenue of $2.40M. Celcuity beat the earnings estimate in 5 of its last 8 reports, moving 7.3% on average across the report.
What is Celcuity’s 52-week high and low?
Celcuity’s 52-week high is $151.02 and its 52-week low is $45.03; it closed at $65.85 on Oct 12, 2026, +33.1% over the past year.
Is Celcuity stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality) and 1 as a headwind (trend). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Celcuity the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.